Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Laurence Delhaes has a total of 357 co-authors. Here are the top co-authors by number of shared publications:

  • Raphaël Enaud

    CF Center, CIC, Hospital Pellegrin-Enfants, 33076 Bordeaux, France

    7 shared publications
  • Patrick Berger

    Centre de Recherche Cardio-Thoracique de Bordeaux, Université de Bordeaux, INSERM, Pessac, France

    6 shared publications
  • Michael Fayon

    CHU Bordeaux, Département de Pédiatrie, CIC-P INSERM 1401 & Université de Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, INSERM U1045, F-33000 Bordeaux, France

    5 shared publications
  • Noémie Coron

    Laboratoire de Parasitologie-Mycologie, Service D'exploration Fonctionnelle Respiratoire, Service de pharmacologie, CIC 1401, CHU de Bordeaux, F-33604 Pessac, France

    5 shared publications
  • Eric Viscogliosi

    CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019–UMR 9017–CIIL–Centre d’Infection et d’Immunité de Lille, University of Lille, F-59000 Lille, France

    4 shared publications
  • Louise-Eva Vandenborght

    Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC 1401, F-33000 Bordeaux, France; Centre de Recherche Cardio-thoracique de Bordeaux, INSERM, U1045, CIC 1401, F-33000 Bordeaux, France; Microbiota Team, Research and Development Department, GenoScreen, Lille, France

    4 shared publications

Latest Publications

  • Open Access

    Endocarditis Due to Scedosporium spp and Lomentospora prolificans : Case Series and Literature Review

    by Carole Vignals, Julien Ternacle, Dea Garcia-Hermoso, Joseph Emmerich, Emilie Catherinot, Laurence Delhaes, Delphine Horeau-Langlard, Jean-Philippe Martellosio, Florent Morio, Olivier Lortholary, et al.

    Background: Scedosporium spp and Lomentospora prolificans are rare fungi involved in mold endocarditis. Methods: We reported cases of Scedosporium spp and L prolificans endocarditis from the French Scedosporiosis/Lomentosporiosis Observational Study (S.O.S.) and performed a literature review of previous reported cases in order to describe their predisposing risk factors, clinical presentation, treatment, and outcomes. Results: We included 30 cases including 4 new cases from the S.O.S. Sixty percent (18/30) of the cases were due to Scedosporium apiospermum complex and 37% (11/30) to L prolificans. Trauma was the main invasive fungal disease host factor (12/30 [40%]), followed by solid organ transplant (10/30 [33%]), short posttransplant delay (median of 45 days), and malignancy (5/30 [17%]). No endocarditis predisposing condition was found in immunocompromised patients (0/16). Eleven cases were healthcare-associated infections (37%). Septic emboli were reported in 93% of the cases (28/30), affecting mainly the central nervous system (CNS) (68%). Pulmonary emboli were present in all right-sided endocarditis (8/8). Blood cultures were negative in 6 cases (27% [6/26]). Surgical valve replacement was performed in 50% of the cases (8/16). Mortality was high whether patients were treated with antifungals only (7/8 [88%]) or with antifungals and surgery (5/7 [71%]). Mortality rose to 100% in the case of CNS emboli. Conclusions: Scedosporium spp and L prolificans endocarditis is a life-threatening fungal disease occurring in both immunocompromised and immunocompetent hosts. It should be considered in the presence of fungemia or embolic complications, particularly in the CNS.

  • Towards a gut-lung axis role in pwCF on CFTR modulators: rationale, clinical evidence and perspectives

    by Maxime Lefranc, Eloise Ramel, Ryan Marsh, James M Tricker, Christopher van der Gast, Jennifer M. Bomberger, Laurence Delhaes

  • Open Access

    The gut microbiome: Recent findings and future opportunities in cystic fibrosis

    by Ryan Marsh, James M Tricker, Laurence Delhaes, Jennifer M Bomberger, Christopher van der Gast


  • Open Access

    Bridging eco-exposome and one health approaches to address emerging infectious diseases through the EMERG project

    by Laurence Delhaes, Baptiste Defaye, Gautier Chauvin, Aurélien Mercier, Jérôme Moreau, Karine Monceau, Cristiana Cravo-Laureau, Gaelle Gonzalez, Jean-Luc Guerin, Nicolas Eterradossi, et al.

    Introduction: Emerging or re-emerging infectious diseases (EIDs) are being increasingly reported and represent a significant burden on public health and global economies, as exemplified by COVID-19 pandemic. Context: Given the current EID importance at the territory level in Nouvelle-Aquitaine (NA, a French southwestern region), we designed a project to address this risk. The EMERG project and consortium (for “Microbial exposome and EID risks: the benefits of a One Health management of zoonotic influenza-related issues and beyond”) aim at deciphering and anticipating EID risks in NA. EMERG project design: EMERG is a transdisciplinary network for evaluating and predicting EID risk and zoonotic potential. EMERG focuses on highly pathogenic avian influenza, zoonotic arboviral infections due to West Nile and Usutu viruses, and the burden of microbial multidrug resistance in NA. Investigative approaches were developed considering the exposome extended to animals, namely the eco-exposome and specifically the microbial eco-exposome. It brings together specialists in human, animal and environmental health. EMERG aim is to provide up-to-date and region-specific data on major EID risks and their determinants in NA, thereby facilitating local management and anticipation of threatening events, epizootics, and epidemics. Implications, limitations, and future directions: In addition to addressing the multiscale nature of complex ecosystems driving EIDs, this transdisciplinary project supports informed decision-making for an adapted regional (NA) policy and can be integrated into larger (national, international) public health initiatives. While EMERG has several limitations, it represents a practical implementation of the One Health approach and eco-exposome concept, which is essential for preventing future EID risks. Here, we focused on project design and organization, and presented examples to demonstrate EMERG feasibility throughout a case study.


  • Open Access

    Fungal lung disease

    by Tavleen Kaur Jaggi, Ritesh Agarwal, Pei Yee Tiew, Anand Shah, Emily C. Lydon, Chadi A. Hage, Grant W. Waterer, Charles R. Langelier, Laurence Delhaes, Sanjay H. Chotirmall

    Fungal lung disease encompasses a wide spectrum of organisms and associated clinical conditions, presenting a significant global health challenge. The type and severity of disease are determined by underlying host immunity and infecting fungal strain. The most common group of diseases are associated with the filamentous fungusAspergillusspecies and include allergic bronchopulmonary aspergillosis, sensitisation, aspergilloma and chronic and invasive pulmonary aspergillosis. Fungal lung disease remains epidemiologically heterogenous and is influenced by geography, environment and host comorbidities. Diagnostic modalities continue to evolve and now include novel molecular assays and biomarkers; however, persisting challenges include achieving rapid and accurate diagnosis, particularly in resource-limited settings, and in differentiating fungal infection from other pulmonary conditions. Treatment strategies for fungal lung diseases rely mainly on antifungal agents but the emergence of drug-resistant strains poses a substantial global threat and adds complexity to existing therapeutic challenges. Emerging antifungal agents and increasing insight into the lung mycobiome may offer fresh and personalised approaches to diagnosis and treatment. Innovative methodologies are required to mitigate drug resistance and the adverse effects of treatment. This state-of-the-art review describes the current landscape of fungal lung disease, highlighting key clinical insights, current challenges and emerging approaches for its diagnosis and treatment.


  • Open Access

    The Molecular Identification and Antifungal Susceptibility of Clinical Isolates of Aspergillus Section Flavi from Three French Hospitals

    by Elie Djenontin, Jean-Marc Costa, Bita Mousavi, Lin Do Ngoc Nguyen, Jacques Guillot, Laurence Delhaes, Françoise Botterel, Eric Dannaoui

    (1) Background: Aspergillus flavus is a cosmopolitan mold with medical, veterinary, and agronomic concerns. Its morphological similarity to other cryptic species of the Flavi section requires molecular identification techniques that are not routinely performed. For clinical isolates of Aspergillus section Flavi, we present the molecular identification, susceptibility to six antifungal agents, and clinical context of source patients. (2) Methods: One hundred forty fungal clinical isolates were included in the study. These isolates, recovered over a 15-year period (2001–2015), were identified based on their morphological characteristics as belonging to section Flavi. After the subculture, sequencing of a part of the β-tubulin and calmodulin genes was performed, and resistance to azole antifungals was screened on agar plates containing itraconazole and voriconazole. Minimum inhibitory concentrations were determined for 120 isolates by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution method. (3) Results: Partial β-tubulin and calmodulin sequences analysis showed that 138/140 isolates were A. flavus sensu stricto, 1 isolate was A. parasiticus/sojae, and 1 was A. nomiae. Many of the isolates came from samples collected in the context of respiratory tract colonization. Among probable or proven aspergillosis, respiratory infections were the most frequent, followed by ENT infections. Antifungal susceptibility testing was available for isolates (n = 120, all A. flavus ss) from one hospital. The MIC range (geometric mean MIC) in mg/L was 0.5–8 (0.77), 0.5–8 (1.03), 0.125–2 (0.25), 0.03–2 (0.22), 0.25–8 (1.91), and 0.03–0.125 (0.061) for voriconazole, isavuconazole, itraconazole, posaconazole, amphotericin B, and caspofungin, respectively. Two (1.67%) isolates showed resistance to isavuconazole according to current EUCAST breakpoints with MICs at 8 mg/L for isavuconazole and voriconazole. One of these two isolates was also resistant to itraconazole with MIC at 2 mg/L. (4) Conclusions: The present characterization of a large collection of Aspergillus belonging to the Flavi section confirmed that A. flavus ss is the predominant species. It is mainly implicated in respiratory and ENT infections. The emergence of resistance highlights the need to perform susceptibility tests on section Flavi isolates.


  • Open Access

    The gut-lung axis in the CFTR modulator era

    by Florian Lussac-Sorton, Éléna Charpentier, Sébastien Imbert, Maxime Lefranc, Stéphanie Bui, Michael Fayon, Patrick Berger, Raphaël Enaud, Laurence Delhaes

    The advent of CFTR modulators represents a turning point in the history of cystic fibrosis (CF) management, changing profoundly the disease’s clinical course by improving mucosal hydration. Assessing changes in airway and digestive tract microbiomes is of great interest to better understand the mechanisms and to predict disease evolution. Bacterial and fungal dysbiosis have been well documented in patients with CF; yet the impact of CFTR modulators on microbial communities has only been partially deciphered to date. In this review, we aim to summarize the current state of knowledge regarding the impact of CFTR modulators on both pulmonary and digestive microbiomes. Our analysis also covers the inter-organ connections between lung and gut communities, in order to highlight the gut-lung axis involvement in CF pathophysiology and its evolution in the era of novel modulators therapies.


  • Open Access

    Effects of Lumacaftor-Ivacaftor on Airway Microbiota-Mycobiota and Inflammation in Patients with Cystic Fibrosis Appear To Be Linked to Pseudomonas aeruginosa Chronic Colonization

    by Raphael Enaud, Florian Lussac-Sorton, Elena Charpentier, Lourdes Velo-Suárez, Jennifer Guiraud, Stéphanie Bui, Michael Fayon, Thierry Schaeverbeke, Macha Nikolski, the LumIvaBiota Study Group, et al.

    The management of cystic fibrosis has been transformed recently by the advent of CFTR modulators, including lumacaftor-ivacaftor. However, the effects of such therapies on the airway ecosystem, particularly on the microbiota-mycobiota and local inflammation, which are involved in the evolution of pulmonary damage, are unclear.


  • Open Access

    Interest of a Commercialized Pneumocystis jirovecii Quantitative PCR to Discriminate Colonization from Pneumocystis Pneumonia according to the Revised EORTC/MSGERC Criteria

    by Florian Lussac-Sorton, Tara Fleur, Thibault Voisin, Nahéma Issa, Élodie Blanchard, Éléna Charpentier, Laurence Delhaes

    Quantitative PCR (qPCR) is highly sensitive to diagnose Pneumocystis jirovecii (Pj) pneumonia (PCP). However, differentiating PCP and colonization remains difficult. This study aimed to establish the performances of the commercialized qPCR MycoGENIE® Pj kit (Ademtech) to distinguish PCP and Pj colonization. Patients with a positive Pj qPCR on bronchoalveolar lavage (BAL) or upper respiratory tract (URT) samples were prospectively included between May 2019 and December 2020 at Bordeaux University Hospital. They were classified in “PCP” or “Pj colonization” groups based on the revised EORTC/MSGERC criteria. The two groups’ results were compared; ROC curves were produced to determine the best thresholds. Excluding the low number of HIV-positive subjects, there were 100 PCP (32 BAL, 68 URT) and 70 Pj colonization (34 BAL, 36 URT). Pj loads were significantly higher in PCP compared to Pj colonization group (p ≤ 0.01). The best cut-offs for PCP diagnosis were 31.45 Cq/8275 copies/mL for BAL and 32.33 Cq/8130 copies/mL for URT (sensitivity = 59.4%, 63.3%, specificity = 82.4%, 88.9%, respectively). Fungal load quantification using MycoGENIE® Pj qPCR helps discriminating PCP from colonization, high fungal loads being indicative of probable PCP. Low load results should be interpreted with caution, in accordance with clinical and radiological signs.


  • Open Access

    The respiratory microbiota alpha-diversity in chronic lung diseases: first systematic review and meta-analysis

    by Marta Avalos-Fernandez, Thibaud Alin, Clémence Métayer, Rodolphe Thiébaut, Raphaël Enaud, Laurence Delhaes

    Background: While there seems to be a consensus that a decrease in gut microbiome diversity is related to a decline in health status, the associations between respiratory microbiome diversity and chronic lung disease remain a matter of debate. We provide a systematic review and meta-analysis of studies examining lung microbiota alpha-diversity in patients with asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) or bronchiectasis (NCFB), in which a control group based on disease status or healthy subjects is provided for comparison. Results: We reviewed 351 articles on title and abstract, of which 27 met our inclusion criteria for systematic review. Data from 24 of these studies were used in the meta-analysis. We observed a trend that CF patients have a less diverse respiratory microbiota than healthy individuals. However, substantial heterogeneity was present and detailed using random-effects models, which limits the comparison between studies. Conclusions: Knowledge on respiratory microbiota is under construction, and for the moment, it seems that alpha-diversity measurements are not enough documented to fully understand the link between microbiota and health, excepted in CF context which represents the most studied chronic respiratory disease with consistent published data to link alpha-diversity and lung function. Whether differences in respiratory microbiota profiles have an impact on chronic respiratory disease symptoms and/or evolution deserves further exploration.